Evidence map›Paper›PMID 40191672›Full record

ArticleWorld journal of clinical cases2025

Nano-drug delivery systems integrated with low radiation doses for enhanced therapeutic efficacy in cancer treatment.

Antonio Pontoriero, Paola Critelli, Marco Zeppieri, Alberto Bosurgi, Stefania Guercio, Maria Caffo, Filippo Flavio Angileri, Silvana Parisi, Salvatore Lavalle, Stefano Pergolizzi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of clinical cases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Antonio PontorieroRadiation Oncology Unit, Department of Biomedical, Dental Science and Morphological and Functional Images, University of Messina, Messina 98125, Italy.
Paola CritelliRadiation Oncology Unit, Department of Biomedical, Dental Science and Morphological and Functional Images, University of Messina, Messina 98125, Italy.
Marco ZeppieriDepartment of Ophthalmology, University Hospital of Udine, Udine 33100, Italy. mark.zeppieri@asufc.sanita.fvg.it.
Alberto BosurgiRadiation Oncology Unit, Department of Biomedical, Dental Science and Morphological and Functional Images, University of Messina, Messina 98125, Italy.
Stefania GuercioNeurosurgery Unit, Department of Biomedical, Dental Science and Morphological and Functional Images, Messina, Italy, Messina 98125, Italy.
Maria CaffoNeurosurgery Unit, Department of Biomedical, Dental Science and Morphological and Functional Images, Messina, Italy, Messina 98125, Italy.
Filippo Flavio AngileriNeurosurgery Unit, Department of Biomedical, Dental Science and Morphological and Functional Images, Messina, Italy, Messina 98125, Italy.
Silvana ParisiRadiation Oncology Unit, Department of Biomedical, Dental Science and Morphological and Functional Images, University of Messina, Messina 98125, Italy.
Salvatore LavalleDepartment of Medicine and Surgery, University of Enna "Kore", Enna 94100, Italy.
Stefano PergolizziRadiation Oncology Unit, Department of Biomedical, Dental Science and Morphological and Functional Images, University of Messina, Messina 98125, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrecision medicine is an emerging field that includes tumor-targeted delivery and tumor microenvironment. This review explores the synergistic potential of combining nano-drug delivery systems with low radiation doses to achieve optimized therapeutic outcomes, particularly in the context of cancer treatment. Nanoparticle-based drug carriers offer precise and targeted delivery, enhancing the therapeutic index of anticancer agents. The use of lower radiation doses has become a focus in radiation oncology to minimize off-target effects on healthy tissues in palliation treatment with high-target volume lesions.

aimTo conduct a bibliometric review of nanomedicine and glioblastoma (GBM), all relevant studies from the last two decades were included.

methodsThe search strategy comprised the keywords "nanomedicine "and "glioblastoma" in the title and/or abstract. All English-language documents from 1 January 2000 to 31 December 2023 were considered for the analysis. R code (version 4.2.0) with R Studio (version 2022.12.0-353) and the Bibliometrix package (version 4.0.1) were used for the analysis. A total of 680 documents were collected.

resultsWe analyzed the bibliometric features of nanomedicine in glioma. With the limitations of the research, our analysis aims to highlight the increasing interest of researchers in the precision medicine field in GBM treatment and lead us to suggest further studies focusing on the association between nanomedicine and radiotherapy.

conclusionDue to the poor prognosis associated with GBM, new therapeutic approaches are necessary. There is an increasing interest in precision medicine, which includes nanomedicine and radiotherapy, for GBM treatment

Indexed as

Combination therapyDrug-deliveryNanomedicineNanoparticlesRadiotherapy

Identifiers

PMID40191672
PMCPMC11670031

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.